Posts tagged ‘Biotech Marketing Consultant’
April 19th, 2011
The Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) earlier this year published 5-year data on the number of approvals and applications for new molecular entities (NME) i.e. new products not previously approved.
Pieter Droppert on Biotech Strategy Blog analyzes this data and discusses what we can conclude from it. Pieter also shares his thoughts on some of the challenges facing the biotechnology industry in bringing new products to market, and some of the factors that may be key to success.
March 25th, 2011
Sally Church, PhD our oncology new products expert, is passionate about making a difference to the lives of patients with cancer. She channels her many talents and energies into helping pharma and biotech companies assess the best targets for their new products. It’s a job that requires science, marketing strategy and commercial awareness; a unique blend of skills.
Sally’s recent post on Pharma Strategy Blog entitled “Accelerated approval and cancer drugs” considers how best to bring new cancer drugs to market? Should promising oncology new products go from phase 2 clinical trials to market without the need for a large and expensive phase 3 registration study? If so, what happens when the data doesn’t pan out as happened with Roche/Genentech’s bevacizumab (Avastin) in breast cancer?
You can read more about Sally’s thoughts on Pharma Strategy Blog.
March 24th, 2011
Icarus Consultants is a marketing strategy consulting company to biotechnology, pharmaceutical and life science companies. We don’t offer marketing communications services.
However, we like to keep our finger on the pulse of the market, so read with interest the recent United States Supreme Court decision in Matrixx Initiatives, Inc. v. Siracusano that involved a failure of Matrixx to share adverse event information with investors.
You may recall the issue of loss of smell associated with use of Zicam Cold Remedy Nasal Gel that contained zinc sulfate.
Matrixx argued that only statistically significant adverse events are material and need to be disclosed to investors, a position the Supreme Court disagreed with. In general terms, the Court held that adverse events that may be linked to a product that could impact a reasonable investor’s decision making need to be disclosed.
What’s the impact of this decision? The Matrixx decision will require companies and their PR agencies to think carefully about the need to include negative information as well as positive when making press releases. Clinical teams will need to talk to investor relations and marketing, something that may be a challenge in the silos of big pharma.
You can read more about this case, and a more in-depth analysis of Justice Sotomayor’s Supreme Court opinion on Biotech Strategy Blog.
March 17th, 2011
It’s a word that one often hears, but did you know that 1 nanometer is a billionth of a meter or one seven-thousandth of the width of a red blood cell? Nanomaterials between 1nm and 100nm are unimaginably small.
As Pieter Droppert discusses today on Biotech Strategy Blog, innovation in nanotechnology is set to provide growth opportunities for life science, pharmaceutical, biotechnology, diagnostics and medical imaging companies.
We can expect to see new drug delivery mechanisms that enhance the efficacy of drugs for cancer, cardiovascular and infectious diseases, as well as new diagnostic tools and imaging agents.
You may not have realized it but nanotechnology is already used in 1000+ consumer products. Think about the titanium particles in your sunscreen as summer arrives.
You can read more about the impact of nanotechnology on Biotech Strategy Blog.
March 9th, 2011
He discusses recent urology clinical research in which new urethras were successfully tissue engineered using cell culture techniques, and then implanted back into five young Mexican boys. The research is a world first and, while experimental, is further progress on the route towards regenerating organs such as kidneys and livers.
Pieter concludes: “Regenerative medicine is an exciting area to watch over the next few years.” As to what the impact this may have on the pharmaceutical and biotechnology industries, you’ll have to read the blog post.
March 7th, 2011
When we do a market assessment or commercial landscape for a therapeutic area or new product, one of the things we look at is emerging new treatments or diagnostics. It’s important to understand the impact these may have on the market opportunity.
Recent research published in the AACR journal Clinical Cancer Research suggests that Engrailed-2 (EN2) may have potential as a biomarker for the diagnosis and treatment of prostate cancer (PC).
In a post on Biotech Strategy Blog, Pieter Droppert discusses the clinical data comparing EN2 to measurement of serum prostate specific antigen (PSA).
March 6th, 2011
Amgen’s denosumab has been shown to reduce skeletal related events (SRE) but not improve overall survival (OS) in prostate cancer.
Icarus Consultants’ oncology new product development expert, Sally Church Ph.D looks at the role of RANKL signaling (the target of denosumab) and recent research on its role in the spread of cancer.
You can gain more insight on this interesting topic from Sally’s Pharma Strategy Blog post.